BSE filing, NSE: EPIGRAL. Summary written from the filing by ALFA Finder's alert engine.
Epigral Ltd: key numbers
- Share price
- ₹874.50
- Market cap
- ₹3,773 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 13.9×Sector 34.1×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Investor Presentation: Key Takeaways
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 27.1% YoY
Epigral Ltd reported revenue from operations of ₹746 Cr (+27.0% YoY) and net profit of ₹65.1 Cr (+27.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +27.1% YoY
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral Legal & Regulatory
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
- Value
- ₹28.11 Cr
Epigral Board Meeting Date
Epigral schedules a board meeting on November 2, 2026 to approve unaudited Q2 and half-year results ended September 30, 2026. The notice is issued for shareholder information.
Epigral Other Announcement
Epigral Limited submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, regarding security dematerialization for the quarter ended September 30, 2026.
Other results update announcements
All →Wonderla Holidays Results Update
Wonderla reports best-ever Q2 with 42% income growth to ₹126 Cr and 90% EBITDA growth. H1 income up 41% to ₹378 Cr driven by new Chennai park.
UPL Results Update
UPL's Q2 FY27 revenue was ₹11,860 Cr with EBITDA of ₹2,312 Cr. H1 operational PATMI rose 33% YoY on sustained margin expansion.
Procter & Gamble Health Results Update
P&G Health's Q2 sales grew 18% to ₹376 crore and PAT rose 26% to ₹112 crore. Growth driven by brand strength and retail execution.
JTL Defence Results Update
JTL Defence reported H1 FY27 revenue of Rs.410 Cr, up 11.4x YoY, with EBITDA of Rs.47 Cr. Adjusted PAT of Rs.3 Cr was impacted by asset revaluation depreciation.
Mold-Tek Packaging Results Update
Mold-Tek reported Q2 FY27 net profit up 36% to Rs 21.06 Cr and H1 profit up 23% to Rs 46.67 Cr. Revenue and sales volumes also rose across both periods.
Eureka Forbes Results Update
Eureka Forbes reported Q2 FY27 revenue of ₹889.6 Cr and PAT of ₹73.3 Cr, both up ~19% YoY. EBITDA margin hit a lifetime high of 13.6%.